Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12376738 | 0.85 | SLC1A3 (0.60) | NPSR1LMNATDP1MEN1KMT2A | |
| SCHEMBL16197361 | 0.84 | TDP1 (0.55) | LMNATDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5453601 | 0.84 | NPSR1 (0.54) | NPSR1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL17908072 | 0.83 | TDP1 (0.53) | NPSR1TDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL120374 | 0.82 | POLB (0.68) | MEN1KMT2AALDH1A1HTTGAA | |
| SCHEMBL28849866 | 0.82 | ADAMTS4 (0.51) | NPSR1LMNATDP1MEN1KMT2A | |
| SCHEMBL12285663 | 0.81 | CYP1A2 (0.59) | NPSR1LMNAPTPN11PTPN1PTPN6 | |
| SCHEMBL13543279 | 0.81 | NPSR1 (0.51) | NPSR1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL13545225 | 0.81 | NPSR1 (0.55) | NPSR1LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL13543487 | 0.81 | CA1 (0.62) | KMT2APTPN11PTPN1PTPN6F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| CN-112442356-B | ABX 3 Preparation method of type stable perovskite quantum dot | 南京邮电大学 | 2022-10-14 | — | — | CN | disclosed |
| CN-112442356-A | ABX3Preparation method of type stable perovskite quantum dot | 南京邮电大学 | 2021-03-05 | — | — | CN | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8501681-B2 | Macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2595989-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| EP-1537421-B1 | A METHOD FOR THE IDENTIFICATION OF DRUG TARGETS | VLAAMS INTERUNIV INST BIOTECH (BE) | 2007-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080038225-A1 | TRIAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | NPSR1 1912/4885LMNA 2271/4885TDP1 2840/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | NPSR1 2144/4885LMNA 2608/4885TDP1 3805/4885 |
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | NPSR1 399/4885LMNA 1681/4885TDP1 69/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | NPSR1 2637/4885LMNA 2228/4885TDP1 3626/4885 |
| US-20080267918-A1 | QUINOXALINYL DIPEPTIDE HEPATITIS C VIRUS INHIBITORS | DPP4, CTSC, PEPD | NPSR1 1583/4885LMNA 3010/4885TDP1 2731/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | NPSR1 1436/4885LMNA 2587/4885TDP1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.